Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, ...

Since 2022, it has been the cause of major epidemics spreading outside endemic ... Drug May Counteract Muscle Loss and Osteoporosis After Rapid Weight Loss Feb. 10, 2025 — Rapid weight loss ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

The first line of pharmacological treatment for schizophrenia is antipsychotic medication. However, antipsychotic medications are ineffective in more than 30% of people with the disorder. This is ...

A research team has successfully developed a super-photostable organic dye after two years of dedicated research demonstrating perseverance akin to that of Marie Curie, who painstakingly extracted ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

The discovery of immunoglobulin G anti-GQ1b antibodies in patients with Fisher syndrome and later in Bickerstaff brainstem encephalitis was crucial in providing the necessary evidence to conclude that ...

Postpartum depression (PPD) is a condition strictly defined in the psychiatric nomenclature as a major depressive episode beginning within the first 4 weeks after childbirth. Considering the fact ...